Crowley Wealth Management Inc. Makes New $723,000 Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Crowley Wealth Management Inc. acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 6,840 shares of the medical equipment provider's stock, valued at approximately $723,000. Zimmer Biomet accounts for 0.6% of Crowley Wealth Management Inc.'s investment portfolio, making the stock its 29th biggest position.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Roman Butler Fullerton & Co. purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at $473,000. Geode Capital Management LLC increased its position in Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock valued at $524,942,000 after purchasing an additional 125,852 shares during the period. M&T Bank Corp raised its holdings in shares of Zimmer Biomet by 48.4% in the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock valued at $2,884,000 after purchasing an additional 8,709 shares in the last quarter. KLCM Advisors Inc. purchased a new stake in shares of Zimmer Biomet in the 4th quarter worth approximately $7,825,000. Finally, Peddock Capital Advisors LLC bought a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $654,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Performance

Shares of ZBH traded down $0.74 during mid-day trading on Tuesday, reaching $110.50. The company had a trading volume of 1,295,710 shares, compared to its average volume of 1,496,400. The stock has a market capitalization of $22.00 billion, a P/E ratio of 24.83, a PEG ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The stock has a 50 day moving average of $106.86 and a two-hundred day moving average of $106.86. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Remove Ads

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the business posted $2.20 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of analyst reports. Royal Bank of Canada lowered their target price on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Truist Financial restated a "hold" rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Stifel Nicolaus lifted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Raymond James decreased their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $124.15.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.95% of the stock is owned by company insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.